Kimberly-Clark Closes Kenvue Deal And Budgets $3.1 Billion In Charges To Integrate It

The diaper-and-tissue maker finished the Kenvue purchase Monday and expects $2.1 billion in run-rate synergies.

Share
Kimberly-Clark Closes Kenvue Deal And Budgets $3.1 Billion In Charges To Integrate It

Kimberly-Clark finished its purchase of Kenvue on Monday, and its board has approved a $3.1 billion integration program that runs through December 31, 2029, according to an 8-K. Each Kenvue share converted into $3.50 in cash plus 0.14625 Kimberly-Clark shares, and Kenvue stopped trading on the New York Stock Exchange.

What Kenvue holders received

Kimberly-Clark, which makes Huggies diapers, Kleenex tissues and Kotex feminine care products, said it has delivered or must deliver about 281,060,840 of its shares to former Kenvue holders. Anyone owed a fractional share gets cash instead.

Kenvue's equity awards, covering options and stock units, became equivalent Kimberly-Clark awards. Performance stock units were converted into restricted units that vest on time alone. Kenvue shares ceased trading at the market open on Monday, the company said.

The cash side was arranged beforehand. Kimberly-Clark closed a $4.9 billion senior notes offering in five tranches, with proceeds set aside alongside cash on hand and commercial paper for the cash consideration and related costs. CFO Nelson Urdaneta said synergy-driven earnings growth, strong free cash flow and scheduled debt maturities would allow de-leveraging on an accelerated basis.

A $3.1 billion integration bill

The program is expected to carry cumulative pre-tax charges of about $3.1 billion, of which about $2.5 billion is cash and $0.6 billion non-cash. Actions began Monday. The company also expects about $1.4 billion in related capital spending through the end of 2029.

The cash charges break down as follows:

  • Supply chain network optimization, about $0.8 billion.
  • Enterprise resource planning and technology integration, about $0.6 billion.
  • Workforce optimization, about $0.4 billion.
  • Advisory services, about $0.4 billion.
  • Program management and other restructuring and integration costs, about $0.3 billion.

The non-cash charges relate mainly to supply chain network optimization. Kimberly-Clark reiterated anticipated run-rate synergies of about $2.1 billion. That includes about $1.9 billion of cost savings captured within three years of closing and about $500 million of incremental profit from revenue synergies, partly offset by about $300 million of reinvestment, captured within four years.

Four segments, a 13-seat board

The combined company will report four segments: North America, at about $18.0 billion in annual sales; EMEA, about $5.0 billion; Asia Pacific Focus Markets, about $4.3 billion; and Enterprise Markets, about $4.3 billion. Those figures combine both companies' 2025 net sales, recast for the new structure.

Three Kenvue directors, Richard Allison, Larry Merlo and Kirk Perry, joined the board, which now has 13 directors. Mae Jemison, Christa Quarles and Jaime Ramirez resigned to make room. The company said the three departures were not the result of any disagreement.

The portfolio now counts 10 billion-dollar brands, including Huggies, Listerine, Tylenol and Neutrogena. CEO Mike Hsu called the closing "a defining moment in Kimberly-Clark's 154-year history."

Premium-priced options for executives

The board's compensation committee approved one-time stock options for executive officers, effective December 1, 2026 and conditioned on the deal closing. Hsu's grant is valued at $6.6 million, Urdaneta's at $2.15 million and Jeffrey Melucci's at $1.8 million.

The exercise price will be the greater of $120.00 or 110% of the closing share price on the grant date. The options vest in full on December 1, 2029, if the executive is still employed.

The options vest on December 1, 2029, one month before the integration program's charges are scheduled to end.

Sources

More on Kimberly-Clark

All Kimberly-Clark (KMB) coverage →